The Latest Breaking News from FDA

The ongoing investigation now entails reports of seven "adverse events" that took place from Oct. 17 through Nov. 1

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

More than 40% of American adults are considered obese, yet the medications many take are rarely tested in bigger bodies

The DAIRY PRIDE Act says it wants to protect consumers. In reality, it's trying to protect dairy farmers from economic competition.

We need to address the unnecessary and wasteful Medsafe approval for tried and tested drugs by much bigger regulatory authorities abroad, argues Dr Eric Crampton

RSV kills 300 kids and thousands of seniors every year. But a new treatment is already facing shortages

The decades-old surgical drug ketamine has found a new use — as an alternative to opioids for patients with chronic pain

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.

Brominated vegetable oil is a food additive that studies show causes organ damage in rats and pigs. It was introduced in the 1920s and is used today in sodas and sports drinks.

The major indexes confirmed the new stock market rally, fueled by tumbling Treasury yields. Arista Networks and Palantir were earnings winners.